EVENITY

EVENITY at a Glance

EVENITY® is a once-monthly injectable treatment for postmenopausal osteoporosis at high fracture risk. It works by inhibiting sclerostin, increasing bone formation and reducing resorption.

• Dose: 210 mg SC, given as two 105 mg injections once monthly
• Use limit: 12 doses (1 year max)
• Mechanism: Dual-action—bone formation + anti-resorption

Performance Benefits for Clinical Use

EVENITY delivers rapid BMD increases and reduces fracture risk across high-risk patient populations.

• 73% relative reduction in new vertebral fractures at 12 months
• 75% reduction in vertebral fractures at 24 months with follow-up antiresorptive use
• 13% increase in lumbar spine BMD at 12 months
• 8.1% lumbar spine BMD gain sustained at 24 months with sequential alendronate
• Outperforms alendronate in BMD gains and fracture prevention

Ideal EVENITY Use Cases and Patient Profiles

Indicated for postmenopausal women with osteoporosis at high risk for fracture—especially those who:

• Have a prior osteoporotic fracture
• Have multiple fracture risk factors
• Are intolerant or unresponsive to other osteoporosis treatments

Note: Not for patients with MI or stroke in the past year

EVENITY Core Ingredients and Their Roles

Each prefilled syringe contains romosozumab-aqqg, a humanized monoclonal antibody.

• Active: Romosozumab-aqqg 105 mg/1.17 mL
• Excipients: Sucrose, calcium, acetate, polysorbate 20, sodium hydroxide, water for injection
• pH adjusted to 5.2

EVENITY Injection Techniques and Application Guide

EVENITY must be administered by a healthcare professional. Each monthly dose requires two injections.

• Dose: 210 mg SC monthly, via two 105 mg prefilled syringes
• Sites: Abdomen, thigh, or upper arm
• Rotate injection sites; avoid irritated or scarred skin
• Missed dose: Reschedule promptly; resume monthly from new date
• Supplement with calcium and vitamin D throughout treatment

EVENITY Storage, Shelf Life, and Handling

Proper storage is critical for drug stability and efficacy.

• Refrigerate at 2–8°C (36–46°F) in original carton
• Do not freeze or shake
• At room temp (max 25°C/77°F): stable for up to 30 days
• Inspect prior to use: solution should be clear to light yellow, free of particles

EVENITY Side Effects: What to Monitor

Monitor patients for both common and serious events.

Common (≥5%):

• Arthralgia
• Headache

Serious:

• Cardiovascular: MI, stroke, cardiovascular death—hazard ratio 1.87 vs alendronate
• Hypocalcemia: Especially in renal impairment; correct before starting
• ONJ and atypical femoral fractures: Evaluate dental health and thigh/groin pain
• Hypersensitivity: Angioedema, rash, urticaria—discontinue if reaction occurs

Key Practitioner Questions About EVENITY Answered

How long can EVENITY be used?

• 12 months max. Afterward, transition to an antiresorptive agent.

Is it effective alone?

• Yes, but follow-up with denosumab or alendronate sustains BMD gains.

Can patients self-inject?

• No. Must be administered by a licensed provider.

Is it safe in renal impairment?

• No dose adjustment needed, but monitor calcium in severe impairment or dialysis.

What happens after stopping?

• Without follow-up treatment, BMD returns to baseline within 12 months

How to Order EVENITY for Your Practice

EVENITY is a prescription biologic available via licensed distributors for in-clinic administration.

Contact Doctor Medica’s customer service representatives for guidance on how to order Evenity online.

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.